VERA
Vera Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.67 / 10
Netural
Liquidity flow evaluation is favorable at 7.75/10, reflecting strong fund inflows, particularly in the Small and Extra-large categories despite a negative overall trend. Analyst sentiment is overwhelmingly bullish with 50% Strong Buy and 33.3% Buy ratings, yet historical win rates vary widely (0% for Goldman Sachs to 100% for TD Cowen). This divergence, combined with a negative price trend (-7.88%), suggests that while money is entering the stock, price action has not yet aligned with bullish expectations.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-19
InstitutionJP Morgan
Times predicted4
Historical Win Rate50.0%
What is the market sentiment for VERA?
- VERA holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.67/10 (Netural).
